Abstract
Review unmet need in the relapsed/refractory (RR) setting in myeloma and B-cell lymphoma and assess incremental benefit provided by CAR-Ts versus RWCP (ciltacabtagene autoleucel/CARVYKTI in MM; axicabtagene ciloleucel/YESCARTA and tisagenlecleucel/KYMRIAH in DLBCL).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have